1. Home
  2. CUPR vs RNTX Comparison

CUPR vs RNTX Comparison

Compare CUPR & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUPR
  • RNTX
  • Stock Information
  • Founded
  • CUPR 2019
  • RNTX 2001
  • Country
  • CUPR Singapore
  • RNTX United States
  • Employees
  • CUPR N/A
  • RNTX N/A
  • Industry
  • CUPR
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUPR
  • RNTX Health Care
  • Exchange
  • CUPR NYSE
  • RNTX Nasdaq
  • Market Cap
  • CUPR 43.2M
  • RNTX 40.3M
  • IPO Year
  • CUPR 2025
  • RNTX N/A
  • Fundamental
  • Price
  • CUPR $7.30
  • RNTX $1.45
  • Analyst Decision
  • CUPR
  • RNTX
  • Analyst Count
  • CUPR 0
  • RNTX 0
  • Target Price
  • CUPR N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • CUPR 300.3K
  • RNTX 37.5K
  • Earning Date
  • CUPR 01-01-0001
  • RNTX 08-13-2025
  • Dividend Yield
  • CUPR N/A
  • RNTX N/A
  • EPS Growth
  • CUPR N/A
  • RNTX N/A
  • EPS
  • CUPR N/A
  • RNTX N/A
  • Revenue
  • CUPR $35,406.00
  • RNTX N/A
  • Revenue This Year
  • CUPR N/A
  • RNTX N/A
  • Revenue Next Year
  • CUPR N/A
  • RNTX N/A
  • P/E Ratio
  • CUPR N/A
  • RNTX N/A
  • Revenue Growth
  • CUPR N/A
  • RNTX N/A
  • 52 Week Low
  • CUPR $3.51
  • RNTX $1.33
  • 52 Week High
  • CUPR $7.46
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • CUPR N/A
  • RNTX N/A
  • Support Level
  • CUPR N/A
  • RNTX N/A
  • Resistance Level
  • CUPR N/A
  • RNTX N/A
  • Average True Range (ATR)
  • CUPR 0.00
  • RNTX 0.00
  • MACD
  • CUPR 0.00
  • RNTX 0.00
  • Stochastic Oscillator
  • CUPR 0.00
  • RNTX 0.00

About CUPR CUPRINA HOLDINGS (CAYMAN) LIMITED

Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: